Jonathan Ryder, MD

Jonathan Ryder, MD

@jonathanrydermd.bsky.social

Adult ID and Assistant Prof at UNMC | Former IUSM IM & Truman State | Abx Stewie, Infxn Prevention, Digital MedEd, Podcasts, Medical History, Reading Non-Fiction, Running/Cycling | Posts are mine

2.4K followers366 following1.1K posts

Jonathan Ryder, MD reposted

id-journal.bsky.social
@id-journal.bsky.social

Study in 8 hospitals with 40,021 pts cut follow-up blood cultures by 18% (goal: 10%) ⬇️ without ↑ stay, mortality, or readmission. Diagnostic stewardship worked.🩸📉

cambridge.orgA quality improvement project to reduce follow-up blood culture utilization through diagnostic stewardshipView abstract Objective:To reduce the use of follow-up blood cultures (FUBC), that is repeat blood cultures (BCs) used to monitor patients for clearance of a prior positive BC, or with new/worsening symptoms after negative BCs, by 10%.Design:Multicenter quality improvement study.Setting:A network of 8 hospitals, including academic tertiary care centers and community hospitals.Participants:40,021 patients, including adult, pediatric, inpatients, and outpatients, for whom blood cultures were ordered over a 24-week period in 2024.Interventions:We implemented a series of iterative Plan-Do-Study-Act (PDSA) cycles to guide clinicians toward appropriate BC ordering. These cycles included educational memos, limiting the ability to order more than one BC at a time, a best practice advisory in the electronic health record to limit BC orders with a prior negative within 72 hours, and a new order panel for BCs that defaulted FUBC to a single set.Results:Prior to the intervention period, FUBCs comprised 29% of all BC orders placed. After the intervention, there was an 18% absolute reduction in FUBC, primarily due to decreased use of paired FUBC sets. There were no increases in the length of stay, in-hospital mortality, or 30-day readmission.Conclusions:We exceeded our goal to decrease FUBCs using diagnostic stewardship. This approach to FUBCs is sustainable and scalable as part of diagnostic stewardship strategies for BC stewardship.

Jonathan Ryder, MD reposted

Contagion®
@contagionlive.bsky.social

Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours. Dr. Joy Juskowich and Dr. Arif Sarwari offer insights around this trial. #IDWeek #IDweek2026 #IDsky www.contagionlive.com/view/early-d...

contagionlive.comEarly Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial | Contagion LivePreliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.

Jonathan Ryder, MD reposted

id-journal.bsky.social
@id-journal.bsky.social

Cefepime–zidebactam showed 91.7% ✅ clinical cure in 60 pts with CR GNB (82.4% MBL producers). 28-day mortality 2.8%⚰️. AEs in 15.3%, serious 2.8%. Well tolerated👍.

academic.oup.comCefepime–Zidebactam for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria, Including Metallo-β-Lactamase Producers: A Phase 2, Open-Label, Single-Arm, Multicenter StudyInfections caused by carbapenem-resistant (CR) Gram-negative bacteria, particularly metallo-β-lactamase (MBL)-producers, have limited treatment options. Cefepime–zidebactam retains activity against these pathogens, but clinical data are limited.MethodsThis prospective, open-label, single-arm, multicenter phase 2 trial enrolled adults with CR Gram-negative infections. Participants received intravenous cefepime–zidebactam for 7–21 days with renal dose adjustment. The Micro-ITT population included participants with a confirmed qualifying CR Gram-negative pathogen, and the CME population included those meeting prespecified evaluability criteria. The primary endpoint was investigator-assessed clinical cure at TOC in the CME population. Outcomes were also reviewed by an external adjudication committee.ResultsSeventy-two participants received treatment; 68 were included in the Micro-ITT population and 60 in the CME population. Among 68 qualifying isolates, 56 (82.4%) were MBL producers, predominantly NDM-β-lactamase producers. Investigator-assessed clinical cure at test-of-cure in the CME population was 91.7% (95% confidence interval, 81.6%–97.2%), and favorable microbiological outcome at TOC was 90.0%. Among participants in the CME population with MBL-producing pathogens, clinical cure was 93.9% and favorable microbiological outcome was 91.8%. External adjudication in the CME population yielded clinical cure of 86.7% and favorable microbiological outcome of 85.0%. Twenty-eight-day mortality was 2.8%. Treatment-related adverse events occurred in 15.3%, and serious treatment-related adverse events occurred in 2.8%.ConclusionsIn 60 evaluable adults with carbapenem-resistant Gram-negative infections, predominantly MBL-producing (81.7%) and cUTI/AP (58.3%), investigator-assessed TOC clinical cure was 91.7%; post hoc adjudicated cure was 86.7%. Day 28 all-cause mortality was 2.8%, and cefepime zidebactam was well tolerated.

Jonathan Ryder, MD reposted

Dimitri Drekonja, MD, MS
@dimitridrekonja.bsky.social

ID is the best specialty; a pet raccoon knocks over a bottle of aromatherapy contaminated by Burkholderia and dies; the exhumed raccoon indeed tests positive for the organism (an emerging pathogen in the US)

Jonathan Ryder, MD reposted

Ilan Schwartz
@germhuntermd.bsky.social

100% these tests should be restricted to ID and perhaps hem onc in setting of a protocol (lung nodules in febrile neutropenia for example)

Joseph Marcus@josephmarcusid.medsky.social

After review, they got rid of standard catalog, but can still be requested by ID: fungitell serum galactomannin fungal blood cultures Led to 90% reduction in orders #IDWeek2026

Jonathan Ryder, MD reposted

Joseph Marcus
@josephmarcusid.medsky.social

Stewarding fungal diagnostics! The story of Ohio State limiting fungal diagnostics and removing fungitell, serum galactomannan (SG), and fungal blood cultures -SG: positivity was 2% at baseline. Positive test only changed 14% of cases. Of the ones who underwent a BAL galact and all ➕ #IDWeek2026

Jonathan Ryder, MD reposted

Joseph Marcus
@josephmarcusid.medsky.social

Check out my mentee’s poster (1565). ID PGY-5 Dr. Martinez-Hernandez presents on genomic changes occurring during the first recorded outbreak of meningococcal conjunctivitis. #IDWeek2026

Jonathan Ryder, MD reposted

Society of Infectious Diseases Pharmacists - SIDP
@sidpharm.bsky.social

Today is packed with research and insights from our SIDP members, featuring 20+ poster presentations and educational sessions! 🔬💊 Swipe through to see who's presenting, and don't miss the opportunity to support your fellow SIDP members! #IDWeek2026 #SIDP #IDPharmacy #AntimicrobialStewardship

Jonathan Ryder, MD reposted

Sébastien Poulin
@sebpoule.bsky.social

Replying to @dralicehan.bsky.social

My Roon feed is 100% med-related, it’s great. No background noise. Still not big enough, but huge potential p.s. it’s difficult to be “active” everywhere… X BS Roon LinkedIn …

Jonathan Ryder, MD reposted

Joseph Marcus
@josephmarcusid.medsky.social

Check out my mentee’s poster (1483). IM PGY-2 Dr. Weil presents on the high frequency of eosinophilia we see in patients receiving ECMO. #IDWeek2026

Jonathan Ryder, MD reposted

Joseph Marcus
@josephmarcusid.medsky.social

Check out my mentee’s poster (1436). ID PGY-5 Dr. Duong presents on the impact of Candida isolation from non-sterile sites on development of invasive candidiasis in patients receiving ECMO. #IDWeek2026

Jonathan Ryder, MD reposted

Ilan Schwartz
@germhuntermd.bsky.social

Replying to @germhuntermd.bsky.social

in the standard ppx, most were on flu Primary endpoint was met: FFS day 90 with rezafungin was non inferior to SAR (ITT) 60% vs 59%

Jonathan Ryder, MD reposted

Ilan Schwartz
@germhuntermd.bsky.social

Replying to @germhuntermd.bsky.social

Next up, another anti fungal presentation! Shariq Haider presenting rezafungin as prophylaxis in allo-HSCT : a double blind double dummy study (ReSPECT) #IDWeek2026 #IDSky

Jonathan Ryder, MD reposted

Ilan Schwartz
@germhuntermd.bsky.social

Replying to @germhuntermd.bsky.social

Primary endpoint : 42 d ACM 23/8% in olorofim arm vs 24.3% in SOC arm - non inferiority was met! Secondary endpoint: survival over time and day 84 all cause mortality - no difference The outcomes were similar to other large studies in IA recently Blinded MSGERC-EORTC response also same between arms

Jonathan Ryder, MD reposted

Ilan Schwartz
@germhuntermd.bsky.social

Replying to @germhuntermd.bsky.social

The clinical question: what to do when you have aspergillosis in a patience in whom you can't treat with first line treatment (a mould active azole). Current SOC is liposomal amphotericin B L-AMB) Olorofim is a dihidroorotate dehydrogenase inhibitor with activity against aspergillus & other moulds

Jonathan Ryder, MD reposted

Ilan Schwartz
@germhuntermd.bsky.social

Attempting Live skeeting from #IDWeek2026 Late breaking antibacterial Starting with inhaled amikacin for MAC pulmonary disease presented by Kevin Winthrop Apparently photos not allowed!!! #IDSky

Jonathan Ryder, MD reposted

Joseph Marcus
@josephmarcusid.medsky.social

Some first day of #IDWeek2026 highlights and lowlights: Highlights: -ID clinicians/researchers are inspirational and proud to be part of this community -Amazing sessions (everyone should watch Mano-y-Mano) Lowlights: -CME doesn’t appear to be active yet :,( (on app or website) #IDSky

Jonathan Ryder, MD reposted

Joseph Marcus
@josephmarcusid.medsky.social

Final Mano y Mano: Should we gown and gloves to prevent inpatient transmission of respiratory virus? (Both debators in PPE) 67% or voters say no #IDWeek2026

Jonathan Ryder, MD reposted

Joseph Marcus
@josephmarcusid.medsky.social

Replying to @josephmarcusid.medsky.social

Final poll: 55% against lock therapy. Summary: 1) come out for Staph aureus, fungal 2) EtOH can cause harms 3) May have a role in prevention 4) Likely to help when line is the source of infection, salvage is preferred, and abx cannot be given through the line

Jonathan Ryder, MD reposted

IDWeek
@idweek.bsky.social

Kick off #IDWeek2026 at this afternoon’s Opening Plenary, “Together We Rise: Courage, Collaboration and the Future,” at 3:45pm in Ballroom ABC! Hear from Atul Gawande, MD, MPH, followed by an esteemed panel discussion.

Jonathan Ryder, MD
@jonathanrydermd.bsky.social

Really enjoyed this episode and look forward to more in this series looking at the history of ID including our profession and personal stories

IDSA@idsainfo.bsky.social

Introducing "Plagues & Icons: The Stories That Shaped ID," a Let's Talk ID series exploring extraordinary lives & history’s most resilient microbes. Dr. Calvin Kunin, 97, an IDSA founder, shares his remarkable life & career with IDSA VP Dr. Max Brito. Watch (bit.ly/4zH3o74) or listen.

Jonathan Ryder, MD reposted

Ilan Schwartz
@germhuntermd.bsky.social

Looking forward to seeing friends from #IDSKy at #IDWeek2026. Please belp spread the word (online and offline). Everyone is invited.

Joseph Marcus@josephmarcusid.medsky.social

For those attending #IDWeek2026, you are invited to an #IDSky Social Media Meet-Up ⏰ Oct 22 8 PM-10:30 PM Place: Marriott Marquis Lobby Bar